TBF1.F - Canntab Therapeutics Limited
| Previous Close | 0.3800 |
| Open | 0.3740 |
| Bid | 0.3400 x 0 |
| Ask | 0.3900 x 0 |
| Day's Range | 0.3740 - 0.3740 |
| 52 Week Range | 0.2620 - 0.7770 |
| Volume | 1,500 |
| Avg. Volume | 59 |
| Market Cap | 9.656M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0870 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Exactus, Inc. Enters into Supply & Distribution Agreement with Canntab Therapeutics to Produce Immediate and Extended Release Tablets
Exactus, Inc. (EXDI) (the “Company”), an industrial hemp farm operator and manufacturer of hemp-derived phytocannabinoid products, today announced that it has entered into a supply and distribution agreement with Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) to produce immediate and extended release tablets. Exactus will provide Canntab a subleased space in their facility in Florida to equip for the purpose of manufacturing advanced hemp derived cannabinoid tablets.
- CNW Group
Canntab provides corporate update
Commercial batch manufacturing of oil-filled gel capsules to begin in Cobourg, leading to a Health Canada request for authorization to begin full scale production and sale. Construction nears completion in Markham, and Canntab intends to request a Health Canada inspection in early fall, to receive Licenced Producer (LP) status. A pharmacist and drug formulation specialist has been hired to assist with our product applications to Health Canada.
- ACCESSWIRE
Canntab Therapeutics Featured in the Canadian Cannabis Investor Magazine
TORONTO, ON / ACCESSWIRE / June 24, 2019 / Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQX: CTABF) (FRA:TBF1.F) (the " Company " or " Canntab "), the leading innovator in hard pill ...
- ACCESSWIRE
Canntab Therapeutics to Present at the 9th Annual LD Micro Invitational
LOS ANGELES, CA / ACCESSWIRE / May 30, 2019 / Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQX: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, today announced that it will be presenting at the 9th annual LD Micro Invitational on Wednesday, June 5th at 11:20AM PST / 2:20PM EST. Richard Goldstein, co-founder and Chief Executive Officer of Canntab Therapeutics will be presenting and meeting with investors. "This year's Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges" stated Chris Lahiji, while waiting in the longest TSA line in history.
- Business Wire
Canntab Signs Term Sheet with Heritage for Processing Hemp for Sale of CBD Filled Gelcaps
Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (TBF1.F) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to announce that it has signed a term sheet with Heritage Cannabis Holdings Corp. (CSE:CANN) ("Heritage") for the purpose of capsule manufacturing (the "Term Sheet"). Under the Term Sheet, Canntab will provide hemp to Heritage's subsidiary Purefarma Solutions ("Purefarma") for the purpose of processing that hemp into high quality CBD oil.
- CNW Group
Canntab signs term sheet with Heritage for processing hemp for sale of CBD filled gelcaps
TORONTO, May 30, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) (OTCQX:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to announce that it has signed a term sheet with Heritage Cannabis Holdings Corp. (CSE:CANN) ("Heritage") for the purpose of capsule manufacturing (the "Term Sheet"). Under the Term Sheet, Canntab will provide hemp to Heritage's subsidiary Purefarma Solutions ("Purefarma") for the purpose of processing that hemp into high quality CBD oil.
- CNW Group
Canntab Receives Cultivation Licence for Industrial Hemp
Additionally, Canntab's application is currently "In Progress" to obtain a Cannabis Licence (Processing- Standard, Federal Sales - Medical) from Health Canada at its Markham, Ontario facility. TORONTO, May 21, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) (OTCQX:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to announce that it has received a cultivation licence for industrial hemp from Health Canada pursuant to the Cannabis Act (Canada) (the "Hemp Licence"). Canntab intends to utilize the Hemp License to secure a substantial amount of hemp biomass that it will grow and cultivate for the extraction of cannabidiol ("CBD") and to conduct research on high CBD hemp varieties, complementing the Company's business plan to also manufacture CBD gel capsules for distribution through its partners in Canada, Australia and Mexico.
- CNW Group
Canntab Advances its Revenue Model with Recent Sales License Approval for FSD Pharma from Health Canada
TORONTO, April 23, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) (OTCQB:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab") is pleased to announce that by virtue of FSD Pharma Inc. ("FSD"), with whom Canntab has entered into a collaboration and profit sharing agreement, being granted a "sale for medical purposes" licence by Health Canada pursuant to the Cannabis Act and Cannabis Regulations (the "FSD Licence"), Canntab is close to being in a position to sell its products and generate revenue. The FSD Licence allows Canntab to produce samples of capsules containing CBD and/or THC, which, if approved by Health Canada, will enable Canntab to launch production and sales out of its manufacturing facility located in Room 6 of FSD's Health Canada approved facility in Cobourg, Ontario.
- GlobeNewswire
Canntab Therapeutics Announces Engagement of Relations Publiques Paradox Inc. for Investor Relations Services
Canntab Therapeutics Limited (CSE:PILL) (the “Company” or “Canntab”) is pleased to announce that, effective March 21, 2019, it has engaged Relations Publiques Paradox Inc. (“Paradox”) to provide investor relations services to the Company. Paradox is a Montreal based investor relations consultancy firm that has been in business for 20 years, and is led by entrepreneur, Jean-Francois Meilleur. Paradox has represented a number of public companies through its extensive network and experience in the capital markets.
- GlobeNewswire
Canntab Enters into Five Year Supply and Loan Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal
Canntab Therapeutics Limited (CSE: PILL, OTCQB: CTABF, FSE: TBF1) (“Canntab” or the “Company”) is pleased to announce that it has entered into a supply and loan agreement (the “Agreement”) with FSD Pharma Inc. (“FSD”) and World Class Extractions Inc. (“World Class”) (collectively, the “Purchasers”) to purchase hemp flower from Thomas Elcome (the “Supplier”). Pursuant to the Agreement, the Supplier grants the Purchasers the right and option to purchase up to CAD $5.0 million of the Supplier’s hemp crop for a period of 5 years commencing in 2019 at a purchase price of CAD $100.0 per kg per 1% of CBD extracted from the flower.
- GlobeNewswire
Canntab Provides Corporate Update
Moving into FSD Pharma and FSD Processing LicenseMackie Research ExtensionDirector Estate Planning InitiativeOTCQB under symbol CTABF TORONTO, Feb. 19, 2019 -- Canntab.
- GlobeNewswire
Canntab Enters into Supply Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal
Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab”), a leader in the development of precision oral dose cannabis tablets and capsules, announced today that it has entered into a supply agreement (the “Agreement”) with FSD Pharma Inc. (“FSD Pharma”) and World Class Extractions Inc. (“World Class”) (the “Purchasers”) to purchase hemp flower from Thomas Elcome (the “Supplier”). Pursuant to the agreement, the Purchasers have agreed to buy approximately 1,000 kg of the Supplier’s 2018 hemp crop at a purchase price of $100.00 per kg per 1% of CBD extracted from the flower.
- GlobeNewswire
FSD Pharma & Canntab Rank Among the Top 2018 Cannabis Stocks -- CFN Media
SEATTLE, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc’s. (CSE:HUGE) (FSDDF) (0K9.F) & Canntab Therapeutics Ltd’s. (CSE:PILL) (TBF1.F) performance in 2018. The cannabis industry experienced significant growth last year, particularly in Canada following the legalization of adult-use cannabis on a federal level. The upcoming legalization of edible products across Canada could open the door to further growth in 2019 and beyond.
- GlobeNewswire
Canntab & FSD Pharma Make Cannabis More Palatable for Doctors -- CFN Media
SEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Canntab Therapeutics Ltd. (CSE:PILL) (TBF1.F). The company is an emerging leader in solid oral dosage cannabis formulations, which are designed to make cannabinoid dosing more accurate and reliable. With 13 patents pending in the United States and Canada, the company is developing instant release, extended release, flash melt, and bi-layer tablets available in 2.5mg, 5mg, and 10mg formulations to ease these concerns.
- GlobeNewswire
Canntab Partners with Leading Surgeon to Conduct Pain Management Trial -- CFN Media
SEATTLE, Dec. 13, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Canntab Therapeutics Ltd. (CSE:PILL) (TBF1.F), The company recently announced a partnership with world-renowned orthopaedic surgeon, Dr. Don Garbuz, MD, to conduct a clinical trial to analyze the efficacy of cannabis as a replacement for opioids in postoperative care. The opioid industry is expected to generate nearly $20 billion in annual revenue by 2020, but the addictive nature of the drug has doctors and patients increasingly concerned. With the legalization of cannabis across Canada and many U.S. states, there’s an opportunity to replace dangerous opioids with efficacious cannabinoids to treat chronic and acute pain.
- GlobeNewswire
Canntab Enters Into a Binding Term Sheet With Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D. for a Clinical Research Trial of Canntab’s Tablets
Partnership formed with Dr. Don Garbuz, an award winning orthopaedic surgeon and medical researcher, credited with over 120 peer reviewed publications. The parties will seek to conduct a clinical study with orthopaedic patients, using Canntab’s sustained release tablets. The study will also seek to show the efficacy of Canntab’s cannabis products for pain management and improvements in patient overall health outcomes.
- GlobeNewswire
Canntab Nears Commercialization with Innovative Cannabis Tablets-- CFN Media
SEATTLE, Nov. 29, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing a key problem facing the medical cannabis industry: dosing and consistency. Unlike pharmaceuticals, medical cannabis is typically prescribed in a smokable form that can produce inconsistent effects between patients. Many pharmaceuticals also offer extended release and features that can make the medicine more efficacious.